These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29334270)

  • 1. Secukinumab in multi-failure psoriatic patients: the last hope?
    Magnano M; Loi C; Patrizi A; Sgubbi P; Balestri R; Rech G; Tasin L; Girardelli CR; Conti A; Odorici G; Campanati A; Offidani AM; Bardazzi F
    J Dermatolog Treat; 2018 Sep; 29(6):583-585. PubMed ID: 29334270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.
    Ho PH; Tsai TF
    J Dermatol; 2018 Nov; 45(11):1353-1356. PubMed ID: 30230584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab for treating plaque psoriasis.
    Rothstein B; Gottlieb A
    Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
    Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response of secukinumab in palmoplantar psoriasis.
    Rocamora V; Garcías-Ladaria J
    Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab in psoriasis and psoriatic arthritis.
    Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.
    Tong Y; Peranteau AJ; Nawas Z; Tyring SK
    Skin Therapy Lett; 2017 Jan; 22(1):1-6. PubMed ID: 28122092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
    Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.
    Amschler K; Phillip S; Mohr J; Wilsmann-Theis D; Poortinga S; Gerdes S; Mössner R
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.